KRAS and colorectal carcinoma: However, given the fact that SAC, compared to conventional colorectal carcinoma, exhibits a higher frequency of KRAS or BRAF mutations and that most SACs are microsatellite stable [3,4], this CRC subtype is especially resistant to targeted therapy such as anti-EGFR and immune checkpoint inhibitors, respectively.